This pathogenic cascade is orchestrated by IFN-γ-STAT1 signaling, and therapeutic inhibition of the JAK2/STAT1 axis with ruxolitinib has been shown to reduce cardiovascular mortality in patients with ICI-induced myocarditis. This evidence concerns the gene STAT1 and myocarditis.